Convalescent Plasma Therapy for Coronavirus Disease 2019
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Convalescent plasma has been used for decades to prevent and treat a wide range of infectious diseases for which no specific treatment is available. The use of convalescent plasma involves transfusing plasma collected from patients who have recovered from a viral illness, in an attempt to transfer virus-neutralizing antibodies and confer passive immunity. In addition to the antiviral mechanisms of neutralizing antibodies, the immunomodulatory effects of plasma components could have benefits. Several small and large-scale studies have shown the effects of convalescent plasma for the treatment of severe coronavirus disease 2019 (COVID-19). In addition to transfusion-related side effects, unexpected side effects such as antibody-dependent enhancement (ADE) may occur during convalescent plasma therapy, but early safety studies have not found any cases of ADE among more than 5,000 participants. With historical precedents and recent clinical studies, convalescent plasma therapy should be considered as a candidate therapy for COVID-19 given the limited effectiveness of antiviral drugs and lack of a vaccine. A system to secure safe collection and use of convalescent plasma should be developed as a response to the pandemic. Further clinical trials should be conducted to determine the safety and efficacy of convalescent plasma therapy concurrently with its clinical use.
Abstract
Convalescent plasma has been used for decades to prevent and treat a wide range of infectious diseases for which no specific treatment is available. The use of convalescent plasma involves transfusing plasma collected from patients who have recovered from a viral illness, in an attempt to transfer virus-neutralizing antibodies and confer passive immunity. In addition to the antiviral mechanisms of neutralizing antibodies, the immunomodulatory effects of plasma components could have benefits. Several small and large-scale studies have shown the effects of convalescent plasma for the treatment of severe coronavirus disease 2019 (COVID-19). In addition to transfusion-related side effects, unexpected side effects such as antibody-dependent enhancement (ADE) may occur during convalescent plasma therapy, but early safety studies have not found any cases of ADE among more than 5,000 participants. With historical precedents and recent clinical studies, convalescent plasma therapy should be considered as a candidate therapy for COVID-19 given the limited effectiveness of antiviral drugs and lack of a vaccine. A system to secure safe collection and use of convalescent plasma should be developed as a response to the pandemic. Further clinical trials should be conducted to determine the safety and efficacy of convalescent plasma therapy concurrently with its clinical use.
참고문헌 (40)
- "Coronavirus disease (COVID-19) pandemic"[URL]
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- 강승지, "Age-Related Morbidity and Mortality among Patients with COVID-19", Infection and Chemotherapy, 52(2), pp.154~164 (2020), 대한감염학회[DOI]
- Kim Sun Bean, "Interim Guidelines on Antiviral Therapy for COVID-19", Infection and Chemotherapy, 52(2), pp.281~304 (2020), 대한감염학회[DOI]
- Beigel JH, "Remdesivir for the treatment of Covid-19 - preliminary report", N Engl J Med, pp.2007764~ (2020)
- RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with Covid-19 - preliminary report", N Engl J Med, pp.2021436~ (2020)
- Mair-Jenkins J, "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology : a systematic review and exploratory meta-analysis", J Infect Dis, 211, pp.80~90 (2015)
- Rojas M, "Ebola virus disease : An emerging and re-emerging viral threat", J Autoimmun, 106, pp.102375~ (2020)
- Planitzer CB, "West Nile virus neutralization by US plasma-derived immunoglobulin products", J Infect Dis, 196, pp.435~440 (2007)
- Casadevall A, "The convalescent sera option for containing COVID-19", J Clin Invest, 130, pp.1545~1548 (2020)
- Luke TC, "Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?", Ann Intern Med, 145, pp.599~609 (2006)
- Hung IF, "Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A(H1N1)2009 virus infection", Clin Infect Dis, 52, pp.447~456 (2011)
- Sahr F, "Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone", J Infect, 74, pp.302~309 (2017)
- van Griensven J, "Evaluation of convalescent plasma for Ebola virus disease in Guinea", N Engl J Med, 374, pp.33~42 (2016)
- Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong", Eur J Clin Microbiol Infect Dis, 24, pp.44~46 (2005)
- Ko JH, "Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection : a single centre experience", Antivir Ther, 23, pp.617~622 (2018)
- Rajendran K, "Convalescent plasma transfusion for the treatment of COVID-19: Systematic review", J Med Virol (2020)
- Rojas M, "Convalescent plasma in Covid-19 : Possible mechanisms of action", Autoimmun Rev, 19, pp.102554~ (2020)
- Garraud O, "Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow", Transfus Clin Biol, 23, pp.39~44 (2016)
- Duan K, "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", Proc Natl Acad Sci U S A, 117, pp.9490~9496 (2020)
- Shen C, "Treatment of 5 critically ill patients with COVID-19 with convalescent plasma", JAMA, 323, pp.1582~1589 (2020)
- Zhang B, "Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection", Chest, 158, pp.e9~e13 (2020)
- 안진영, "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea", Journal of Korean Medical Science, 35(14), pp.1~8 (2020), 대한의학회[DOI]
- Zeng QL, "Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019", J Infect Dis, 222, pp.38~43 (2020)
- Salazar E, "Treatment of coronavirus disease 2019(COVID-19)patients with convalescent plasma", Am J Pathol, 190, pp.1680~1690 (2020)
- Perotti C, "Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial", Haematologica (2020)
- Abolghasemi H, "Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study", Transfus Apher Sci (2020)
- Li L, "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19 : A randomized clinical trial", JAMA, 324, pp.1~11 (2020)
- Piechotta V, "Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review", Cochrane Database Syst Rev, 7, pp.CD013600~ (2020)
- Joyner MJ, "Early safety indicators of COVID-19 convalescent plasma in 5, 000 patients", J Clin Invest, 130, pp.4791~4797 (2020)
- Semple JW, "Transfusion-associated circulatory overload and transfusion-related acute lung injury", Blood, 133, pp.1840~1853 (2019)
- Smatti MK, "Viral-induced enhanced disease illness", Front Microbiol, 9, pp.2991~ (2018)
- Wan Y, "Molecular mechanism for antibody-dependent enhancement of coronavirus entry", J Virol, 94, pp.e02015~e02019 (2020)
- Wang Q, "Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates", ACS Infect Dis, 2, pp.361~376 (2016)
- "Recommendations for investigational COVID-19 convalescent plasma"[URL]
- "Guidelines for collecting convalescent plasma of COVID-19"[URL]
- Long QX, "Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections", Nat Med, 26, pp.1200~1204 (2020)
- Wang K, "Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection", Clin Infect Dis (2020)
- Harvala H, "Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020", Euro Surveill, 25, pp.2001260~ (2020)
- Juno JA, "Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19", Nat Med (2020)